A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
Harrison M, Hahn N, Pili R, Oh W, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs 2010, 29: 1465-1474. PMID: 20499131, PMCID: PMC3042040, DOI: 10.1007/s10637-010-9455-x.Peer-Reviewed Original ResearchConceptsCastrate-resistant prostate cancerMetastatic castrate-resistant prostate cancerTaxane-refractoryPrimary endpointProstate cancerAdverse eventsProgression-free survivalPhase II studyTaxane-based regimensClinically significant activityFDG-PET scansLiver function testsFDG-PET imagingMetabolic responsePSA responseAggressive biologyEvidence of biological activityExploratory endpointsStudy drugSecondary endpointsPreclinical dataGastrointestinal hemorrhageFDG-PETMonth 6Pre-chemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply